$INMB

Inmune Bio, Inc.

CIK:0001711754|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
REVENUE				$ 50
OPERATING EXPENSES
General and administrative	2,279	2,253	4,450	4,569
Research and development	(803)	5,804	2,838	13,443
Impairment of acquired in-process research and development intangible assets		16,514		16,514
Total operating expenses	1,476	24,571	7,288	34,526
LOSS FROM OPERATIONS	(1,476)	(24,571)	(7,288)	(34,476)
OTHER INCOME, NET	203	113	608	279
NET LOSS	$ (1,273)	$ (24,458)	$ (6,680)	$ (34,197)
Net loss per common share – basic (in Dollars per share)	$ (0.05)	$ (1.05)	$ (0.25)	$ (1.49)
Net loss per common share – diluted (in Dollars per share)	$ (0.05)	$ (1.05)	$ (0.25)	$ (1.49)
Weighted average common shares outstanding – basic (in Shares)	26,718,507	23,298,455	26,652,250	22,899,539
Weighted average common shares outstanding – diluted (in Shares)	26,718,507	23,298,455	26,652,250	22,899,539
COMPREHENSIVE LOSS
Net loss	$ (1,273)	$ (24,458)	$ (6,680)	$ (34,197)
Other comprehensive loss – foreign currency translation	(96)	(153)	(86)	(188)
Total comprehensive loss	$ (1,369)	$ (24,611)	$ (6,766)	$ (34,385)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,680)	$ (34,197)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	2,855	3,610
Gain on settlement of accounts payable	(91)
Depreciation expense	118
Impairment of acquired research and development intangible assets		16,514
Changes in operating assets and liabilities:
Research and development tax credit receivable	(129)	(424)
Other tax receivable	(97)	(322)
Prepaid expenses	(26)	(174)
Other assets	58	(491)
Accounts payable and accrued liabilities	(2,624)	1,132
Accounts payable and accrued liabilities – related parties		159
Deferred liabilities		(6)
Operating lease liabilities	38
Net cash used in operating activities	(6,578)	(14,199)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(430)	(706)
Net cash used in investing activities	(430)	(706)
CASH FLOWS FROM FINANCING ACTIVITIES:
Sale of common stock for cash	584	27,544
Exercise of warrants for cash	130	1
Exercise of stock options for cash	35
Net cash provided by financing activities	749	27,545
Impact on cash from foreign currency translation	(81)	(188)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(6,340)	12,452
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	24,751	20,922
CASH AND CASH EQUIVALENTS AT END OF PERIOD	18,411	33,374
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash paid for income taxes
Cash paid for interest
SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES
Right of use assets obtained in exchange for lease obligations	$ 587

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
CURRENT ASSETS
Cash and cash equivalents	$ 18,411	$ 24,751
Research and development tax credit receivable	4,413	4,284
Other tax receivable	354	257
Prepaid expenses and other current assets	621	595
TOTAL CURRENT ASSETS	23,799	29,887
Equipment, net	1,262	955
Operating lease – right of use asset	1,247	914
Other assets	537	595
TOTAL ASSETS	26,845	32,351
CURRENT LIABILITIES
Accounts payable and accrued liabilities	5,053	7,768
Operating lease, current liabilities	812	623
TOTAL CURRENT LIABILITIES	5,890	8,416
Long-term operating lease liability	593	411
TOTAL LIABILITIES	6,483	8,827
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding
Common stock, $0.001 par value, 200,000,000 shares authorized, 27,653,789 and 26,585,258 shares issued and outstanding, respectively	28	27
Additional paid-in capital	237,688	233,271
Subscription receivable	(814)
Accumulated other comprehensive loss	(823)	(737)
Accumulated deficit	(215,717)	(209,037)
TOTAL STOCKHOLDERS’ EQUITY	20,362	23,524
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	26,845	32,351
Related Party
CURRENT LIABILITIES
Accounts payable and accrued liabilities – related parties	$ 25	$ 25